A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, sulfamethoxazole, oxicam and nevirapine. Recently, a strong association between carbamazepine and allopurinol induced SJS or TEN has been described with respectively, HLA-B*1502 and HLA-B*5801 in a Han Chinese population from Taiwan and other Asian countries. OBJECTIVE: The objective is to further investigate the relationship between SJS/TEN and HLA-B in a large number of patients in a European population. METHODS: HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN. We focused on patients related to 'high-risk' drugs including: 31 cases related to allopurinol, 28 to sulfamethoxazole, 19 to lamotrigine and 14 to oxicam. RESULTS: Sixty-one percent of 31 allopurinol-induced SJS/TEN patients carried the HLA-B*5801 allele and the figure was 55% for 27 patients of European ancestry [odds ratio=80 (34-187)], (P<10(-6)) as previously observed in Han Chinese. For other drugs, two rare alleles showed a weaker association with SJS/TEN in a limited number of patients: B*38 for sulfamethoxazole or lamotrigine-related patients, and B*73 for oxicam. CONCLUSION: At variance with prior results in Asia, this study shows that even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease. Further investigations are necessary to delineate the exact role of the HLA region in SJS/TEN, and to look for other associations in other regions of the genome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807 · cited 1×
“Adverse reactions to drugs are important causes of morbidity and even of death in developed countries [ 1 ].”
BackgroundA marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380 · cited 1×
“In the previous years growing interest focused on the role of HLA in severe drug reactions, which was initiated by the demonstration that HLA-B*5701, was strongly associated with hypersensitivity to the anti-HIV medication abacavir [ 16 ,17].”
BackgroundHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284 · cited 4×
“In Taiwan the carrier prevalence of B*5801 was 20% in a control group [ 21 ].”
BackgroundInfluentialMockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Self-citationInhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005 · cited 1×
“The initial events triggering the immune reaction remain to be identified [ 10 ].”
BackgroundInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūtė, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 925
Sassolas, B., Haddad, C., Mockenhaupt, M., Dunant, A., Liss, Y., Bork, K., Haustein, U. F., Vieluf, D., Roujeau, J. C., & Le Louet, H. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.252 · Cited by 758
Self-citationToxic epidermal necrolysis and Stevens-Johnson syndrome
Harr, T., & French, L. E. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-39 · Cited by 693
“This RegiSCAR study revealed that HLA-B*1502 is neither a marker for carbamazepine, sulfamethoxazole, lamotrigine, or NSAID’s of oxicam-type induced SJS/TEN nor a sufficient explanation for the cause of the disease in Europeans [35,36].”
BackgroundOzeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., Ikezawa, Z., Iijima, M., Shiohara, T., Hashimoto, K., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq537 · Cited by 515
Severe cutaneous adverse reactions to drugs
Duong, T. A., Valeyrie-Allanore, L., Wolkenstein, P., & Chosidow, O. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30378-6 · Cited by 445
Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J.-I., Furuya, H., Takahashi, Y., Muramatsu, M., et al. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1617 · Cited by 410
Tassaneeyakul, W., Jantararoungtong, T., Chen, P., Lin, P.-Y., Tiamkao, S., Khunarkornsiri, U., Chucherd, P., Konyoung, P., Vannaprasaht, S., Choonhakarn, C., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328330a3b8 · Cited by 401
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Lerch, M., Mainetti, C., Terziroli Beretta-Piccoli, B., & Harr, T. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8654-z · Cited by 355
“is a significant association of HLA-B*5801 with allopurinolSJS/TEN [123], though to a lower extent compared to the Han Chinese [133] or Thai populations [134].”
ResultDrug Reaction With Eosinophilia and Systemic Symptoms: A Retrospective Study of 60 Cases
Chen, Y.-C., Chiu, H.-C., & Chu, C.-Y. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.198 · Cited by 350
The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis
Mockenhaupt, M. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.66 · Cited by 347
Self-citationSchwartz, R. A., McDonough, P. H., & Lee, B. W. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.05.002 · Cited by 338
Leckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George, A. L., Tran, E., Berger, R., Müller, D. J., Whirl-Carrillo, M., Caudle, K. E., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.103 · Cited by 335
Phillips, E. J., Sukasem, C., Whirl‐Carrillo, M., Müller, D. J., Dunnenberger, H. M., Chantratita, W., Goldspiel, B., Chen, Y., Carleton, B. C., George, A. L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1004 · Cited by 328
“However, it is important to note that in one study, in a group of individuals thought to be of European origin, four of 12 individuals with SJS/TEN carried the HLA-B*15:02 allele.(24) Subsequently, they were found to have some Southeast Asian ancestry.”
BackgroundChung, W., Chung, W., Liu, Z., Chen, C.-H., Hsih, M., Hui, R. C., Chu, C., & Chen, Y.-T. (2010) · Pharmacogenomics · doi:10.2217/pgs.09.162 · Cited by 325
Schwartz, R. A., McDonough, P. H., & Lee, B. W. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.05.003 · Cited by 316
Mayorga, C., Celik, G., Rouzaire, P., Whitaker, P., Bonadonna, P., Rodrigues‐Cernadas, J., Vultaggio, A., Brockow, K., Caubet, J. C., Makowska, J., et al. (2016) · Allergy · doi:10.1111/all.12886 · Cited by 314
Idiosyncratic Adverse Drug Reactions: Current Concepts
Uetrecht, J., & Naisbitt, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007450 · Cited by 310
“This in turn might explain why strong associations between expression of specific HLA alleles and SMX reactions have not been identified (Lonjou et al., 2008; Alfirevic et al., 2009).”
BackgroundStamp, L. K., Taylor, W. J., Jones, P. B., Dockerty, J. L., Drake, J., Frampton, C., & Dalbeth, N. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34488 · Cited by 296
Cho, Y.-T., Yang, C.-W., & Chu, C.-Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061243 · Cited by 286
“In addition, HLA-A*31:01 increases the risk of developing carbamazepine-induced DRESS syndrome but also increases the risk of developing SJS/TEN syndrome in individuals of Japanese and European descents [92,93].”
BackgroundCarbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans
Kim, S., Lee, K. W., Song, W., Kim, S., Jee, Y., Lee, S. M., Kang, H., Park, H., Cho, S., Park, S.-H., et al. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.08.010 · Cited by 272
Levi, N., Bastuji-Garin, S., Mockenhaupt, M., Roujeau, J.-C., Flahault, A., Kelly, J. P., Martin, E., Kaufman, D. W., & Maison, P. (2009) · Pediatrics · doi:10.1542/peds.2008-1923 · Cited by 270
Self-citationTangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M., & Tassaneeyakul, W. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.4114 · Cited by 263
The genetics of hyperuricaemia and gout
Reginato, A. M., Mount, D. B., Yang, I., & Choi, H. K. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.144 · Cited by 251
Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Furuya, H., Takahashi, Y., Muramatsu, M., Kinoshita, S., et al. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02766.x · Cited by 248
“As for carbamazepine-induced SJS/TEN, involvement of HLA-B*1502 in Han Chinese SJS/TEN patients has been reported (Chung et al., 2004), and has been confirmed in Asians in Hong Kong (Man et al., 2007), Europe (Lonjou et al., 2006), Thailand (Locharernkul et al., 2008), and India (Mehta et al., 2009).”
BackgroundInfluentialStevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update
Dodiuk-Gad, R. P., Chung, W.-H., Valeyrie-Allanore, L., & Shear, N. H. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0158-0 · Cited by 247
“In vitro assessments Table 4 High-risk drugs for Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) [65, 152, 153] Drugs General population [65]a Children [152]b Africa [153]c Allopurinol 4 Highest incidence in Europe and Israel 4 Antibacterial sulfonamides 4 4 4 Highest incidence in Africa Antiepilepti…”
BackgroundInfluentialHershfield, M. S., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Thorn, C. F., Klein, T. E., & Lee, M. T. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.209 · Cited by 245
Kurose, K., Sugiyama, E., & Saito, Y. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-111 · Cited by 234
White, K. D., Chung, W.-H., Hung, S.-I., Mallal, S., & Phillips, E. J. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.05.050 · Cited by 227
“Allelic variation in the genes that encode the MHC family of proteins is often associated with risk of T cell–mediated drug hypersensitivity reactions in certain populations (Table I).(12-69) This review focuses on the purely T cell–mediated drug hypersensitivity reactions, although the same principles and models like…”
BackgroundStevens–Johnson syndrome and toxic epidermal necrolysis
Borchers, A. T., Lee, J. L., Naguwa, S. M., Cheema, G. S., & Gershwin, M. E. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.06.004 · Cited by 224
Hama, N., Abe, R., Gibson, A., & Phillips, E. J. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.02.004 · Cited by 220
Somkrua, R., Eickman, E. E., Saokaew, S., Lohitnavy, M., & Chaiyakunapruk, N. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-118 · Cited by 219
“They included the duration of exposure to allopurinol no longer than 42 days [12], 60 days [15], or 3 months [10,13], and improvement of symptoms after drug discontinuation [10,13].”
BackgroundMethodInfluentialAmstutz, U., Shear, N. H., Rieder, M. J., Hwang, S., Fung, V., Nakamura, H., Connolly, M. B., Ito, S., Carleton, B. C., & the CPNDS clinical recommendation group (2014) · Epilepsia · doi:10.1111/epi.12564 · Cited by 210
“On the other hand, no carriers of any HLA-B*15 allele were observed in eight European CBZ-SJS/TEN cases.(58) Similarly, only one carrier of HLA-B*15:11 was observed among 42 CBZ-SJS/TEN cases in Thailand.”
BackgroundKo, T.-M., Tsai, C.-Y., Chen, S.-Y., Chen, K.-S., Yu, K.-H., Chu, C.-S., Huang, C.-M., Wang, C.-R., Weng, C.-T., Yu, C.-L., et al. (2015) · BMJ · doi:10.1136/bmj.h4848 · Cited by 209
Allopurinol hypersensitivity: investigating the cause and minimizing the risk
Stamp, L. K., Day, R. O., & Yun, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.132 · Cited by 204
HLA and Pharmacogenetics of Drug Hypersensitivity
Pavlos, R., Mallal, S., & Phillips, E. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.108 · Cited by 197
Chung, W.-H., Chang, W.-C., Stocker, S. L., Juo, C.-G., Graham, G. G., Lee, M.-H. H., Williams, K. M., Tian, Y.-C., Juan, K.-C., Jan Wu, Y.-J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205577 · Cited by 195
Adverse drug events in the oral cavity
Yuan, A., & Woo, S.-B. (2015) · Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2014.09.009 · Cited by 193
Toxic epidermal necrolysis: Review of pathogenesis and management
Downey, A. W., Jackson, C., Harun, N., & Cooper, A. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.09.029 · Cited by 190
Sotozono, C., Ueta, M., Koizumi, N., Inatomi, T., Shirakata, Y., Ikezawa, Z., Hashimoto, K., & Kinoshita, S. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.12.048 · Cited by 190
Hasegawa, A., & Abe, R. (2020) · F1000Research · doi:10.12688/f1000research.24748.1 · Cited by 188
Severe drug‐induced skin reactions: clinical pattern, diagnostics and therapy
Mockenhaupt, M. (2009) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2008.06878.x · Cited by 187
Self-citationAllopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012
Ramasamy, S. N., Korb-Wells, C. S., Kannangara, D. R. W., Smith, M. W. H., Wang, N., Roberts, D. M., Graham, G. G., Williams, K. M., & Day, R. O. (2013) · Drug Safety · doi:10.1007/s40264-013-0084-0 · Cited by 182
“The presence of the HLA-B*5801 allele was demonstrated in 166 patients [125, 241, 271, 276, 278, 279, 311, 327, 329], 160 of whom were from the Singer and Wallace AH”
BackgroundInfluentialSJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation
White, K. D., Abe, R., Ardern-Jones, M., Beachkofsky, T., Bouchard, C., Carleton, B., Chodosh, J., Cibotti, R., Davis, R., Denny, J. C., et al. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.11.023 · Cited by 181
Self-citationTohkin, M., Kaniwa, N., Saito, Y., Sugiyama, E., Kurose, K., Nishikawa, J., Hasegawa, R., Aihara, M., Matsunaga, K., Abe, M., et al. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.41 · Cited by 181
Yang, C.-Y., Chen, C.-H., Deng, S.-T., Huang, C.-S., Lin, Y.-J., Chen, Y.-J., Wu, C.-Y., Hung, S.-I., & Chung, W.-H. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.3536 · Cited by 180
Karnes, J. H., Rettie, A. E., Somogyi, A. A., Huddart, R., Fohner, A. E., Formea, C. M., Ta Michael Lee, M., Llerena, A., Whirl‐Carrillo, M., Klein, T. E., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2008 · Cited by 179
“However, this allele may also occur in other populations throughout the world that have yet to be studied, and patients may be unaware of, or fail to disclose, Asian ancestry in their families.(23,24) If a patient is phenytoin-naïve and HLA-B*15:02 negative, the patient has a normal risk of phenytoin-induced SJS/TEN a…”
Drug hypersensitivity: Pharmacogenetics and clinical syndromes
Phillips, E. J., Chung, W.-H., Mockenhaupt, M., Roujeau, J.-C., & Mallal, S. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.046 · Cited by 178
“However, this association was not found in European patients with CBZassociated SJS/TEN.(4,38)Man et al(6) enrolledHanChinese living in Hong Kong and validated that HLA-B*1502 was associated with SCARs induced by CBZ, phenytoin, and potentially lamotrigine.”
BackgroundResultInfluentialSelf-citationHLA Association with Drug-Induced Adverse Reactions
Fan, W., Shiao, M., Hui, R. C., Su, S., Wang, C., Chang, Y., & Chung, W. (2017) · Journal of Immunology Research · doi:10.1155/2017/3186328 · Cited by 170
“Sulphamethoxazole B∗38 SJS/TEN European [57]”
Treating to target: a strategy to cure gout
Pérez-Ruiz, F. (2009) · Rheumatology · doi:10.1093/rheumatology/kep087 · Cited by 167
Kohanim, S., Palioura, S., Saeed, H. N., Akpek, E. K., Amescua, G., Basu, S., Blomquist, P. H., Bouchard, C. S., Dart, J. K. G., Gai, X., et al. (2015) · The Ocular Surface · doi:10.1016/j.jtos.2015.10.002 · Cited by 167
Yun, J. J., Marcaida, M. J., Eriksson, K., Jamin, H., Fontana, S., Pichler, W. J., & Yerly, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302306 · Cited by 160
“Recent studies (2, 3) showed that ALP-induced SCAR is strongly associated with the HLA-B*58:01 allele.”
BackgroundMethodGonçalo, M., Coutinho, I. A., Teixeira, V., Gameiro, A. R., Brites, M. M., Nunes, R., & Martinho, A. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12389 · Cited by 160
An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity
Chen, C.-B., Abe, R., Pan, R.-Y., Wang, C.-W., Hung, S.-I., Tsai, Y.-G., & Chung, W.-H. (2018) · Journal of Immunology Research · doi:10.1155/2018/6431694 · Cited by 159
“Oxicam NSAIDs B∗73:01 SJS/TEN European [93]”
BackgroundInfluentialSuccessful Treatment of Stevens-Johnson Syndrome with Steroid Pulse Therapy at Disease Onset
Araki, Y., Sotozono, C., Inatomi, T., Ueta, M., Yokoi, N., Ueda, E., Kishimoto, S., & Kinoshita, S. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.12.040 · Cited by 159
Mechanisms of Adverse Drug Reactions
Pirmohamed, M. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch30 · Cited by 151
Maahs, D. M., Caramori, M. L., Cherney, D. Z. I., Gałecki, A. T., Gao, C., Jalal, D. I., Perkins, B. A., Pop‐Busui, R., Rossing, P. R., Mauer, M. S., et al. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0381-0 · Cited by 150
“About 60 % of allopurinol induced cases of SJS and toxic epidermal necrolysis (TEN) carry the HLA-B*5801 allele [67] and HLA-B*5801 positive persons are estimated to be about 300 times more likely to develop SJS/TEN than those without this allele [68•].”
BackgroundControversies in drug allergy: In vitro testing
Mayorga, C., Ebo, D. G., Lang, D. M., Pichler, W. J., Sabato, V., Park, M. A., Makowska, J. S., Atanasković‐Marković, M., Bonadonna, P., & Jares, E. J. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.022 · Cited by 148
Lauschke, V. M., Zhou, Y., & Ingelman‐Sundberg, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.002 · Cited by 146
Jung, J., Song, W., Kim, Y.-S., Joo, K. W., Lee, K., Kim, S.-H., Park, H., Chang, Y., Cho, S., Min, K. ‐., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr060 · Cited by 142
“HLA-B*5801 is known as a risk marker for the development of allopurinol-induced SJS/ TEN or drug hypersensitivity syndrome because of its remarkably high prevalence in patient groups [8–11].”
BackgroundZhang, Y., Wang, J., Zhao, L., Peng, W., Guo-qing, S., Xue, L., Xiao-xian, Z., Xiao-jing, H., Chun-yan, G., & Miao, L.-Y. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1009-4 · Cited by 140
“[ 7 ] and in Japanese [8] did not find the same association.”
BackgroundGenomewide Pharmacogenetics of Bisphosphonate-Induced Osteonecrosis of the Jaw: The Role of RBMS3
Nicoletti, P., Cartsos, V. M., Palaska, P. K., Shen, Y., Floratos, A., & Zavras, A. I. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0202 · Cited by 140
“Human leukocyte antigen (HLA) haplotype variation is often associated with adverse drug reactions that have an immune-related pathogenesis [34–36].”
BackgroundYun, J. J., Mattsson, J., Schnyder, K., Fontana, S., Largiadèr, C. R., Pichler, W. J., & Yerly, D. (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12184 · Cited by 136
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Harr, T., & French, L. E. (2012) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000335627 · Cited by 131
Gout and its comorbidities: implications for therapy
Stamp, L. K., & Chapman, P. T. (2012) · Rheumatology · doi:10.1093/rheumatology/kes211 · Cited by 129
Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia
Ding, W. Y., Lee, C. K., & Choon, S. E. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04481.x · Cited by 127
Kulkantrakorn, K., Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Prabmeechai, N., Vannaprasaht, S., Chumworathayi, P., Chen, P., & Sritipsukho, P. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2011.00479.x · Cited by 125
Stevens-Johnson syndrome: The role of an ophthalmologist
Jain, R., Sharma, N., Basu, S., Iyer, G. K., Ueta, M., Sotozono, C., Kannabiran, C., Rathi, V. M., Gupta, N. M., Kinoshita, S., et al. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2016.01.004 · Cited by 124
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout
Chao, J., & Terkeltaub, R. A. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0019-z · Cited by 122
Copy number variants in pharmacogenetic genes
He, Y., Hoskins, J. M., & McLeod, H. L. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.007 · Cited by 122
Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe
Génin, E., Schumacher, M. C., Roujeau, J., Naldi, L., Liß, Y., Kazma, R., Sekula, P., Hovnanian, A., & Mockenhaupt, M. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-52 · Cited by 122
“An investigation of HLA-B associations in European samples did not detect the association between the HLA-B*1502 allele and carbamazepine-induced SJS/TEN but did report a strong but not complete association between HLA-B*5801 and the allopurinol-induced disease [16,17].”
Self-citationPharmacogenomic biomarkers: new tools in current and future drug therapy
Sim, S. C., & Ingelman‐Sundberg, M. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.008 · Cited by 121
Pharmacogenomics of adverse drug reactions
Daly, A. K. (2013) · Genome Medicine · doi:10.1186/gm409 · Cited by 121
“This association was later shown to extend to other ethnic groups [30].”
Chung, W., Pan, R., Chu, M.-T., Chin, S.-W., Huang, Y.-L., Wang, W.-C., Chang, J., & Chung, W. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.165 · Cited by 119
Erythema Multiforme, Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
Breathnach, S. M. (2010) · Wiley eBooks · doi:10.1002/9781444317633.ch76 · Cited by 118
Pharmacogenetics of Drug Hypersensitivity
Phillips, E. J., & Mallal, S. A. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.77 · Cited by 117
HLAs: Key regulators of T‐cell‐mediated drug hypersensitivity
Redwood, A., Pavlos, R. K., White, K. D., & Phillips, E. J. (2017) · HLA · doi:10.1111/tan.13183 · Cited by 117
Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances
Bellón, T. (2019) · Drug Safety · doi:10.1007/s40264-019-00825-2 · Cited by 117
Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions
Gibson, A., Deshpande, P., Campbell, C. N., Krantz, M. S., Mukherjee, E. M., Mockenhaupt, M., Pirmohamed, M., Palubinsky, A. M., & Phillips, E. J. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.12.005 · Cited by 116
Self-citationUsing Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions
Daly, A. K. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134743 · Cited by 115
Multidisciplinary care in Stevens-Johnson syndrome
Shanbhag, S. S., Chodosh, J., Fathy, C. A., Goverman, J. M., Mitchell, C. M., & Saeed, H. N. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319894469 · Cited by 115
Tempark, T., Satapornpong, P., Rerknimitr, P., Nakkam, N., Saksit, N., Wattanakrai, P., Jantararoungtong, T., Koomdee, N., Mahakkanukrauh, A., Tassaneeyakul, W., et al. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000306 · Cited by 115
Kim, S., Kim, M., Lee, K. W., Kim, S., Kang, H., Park, H., & Jee, Y. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.54 · Cited by 111
Wang, Y., Chen, C., Tassaneeyakul, W., Saito, Y., Aihara, M., Choon, S. E., Lee, H. Y., Chang, M., Roa, F. D., Wu, C., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1071 · Cited by 111
“The frequencies of these specific alleles have also been found to be correlated with the increased risks of SJS/TEN induced by carbamazepine and allopurinol in Asian populations.(7,8) However, the strong HLA-B*15:02 association with carbamazepineinduced SJS/TEN was not found in European populations.”
BackgroundKazeem, G., Cox, C. J., Aponte, J. L., Messenheimer, J. A., Brazell, C., Nelsen, A. C., Nelson, M. R., & FOOT, E. A. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832c347d · Cited by 111
Update on gout management: what is old and what is new
Afinogenova, Y., Danve, A. S., & Neogi, T. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000861 · Cited by 109
Pharmacogenetics of cutaneous adverse drug reactions
Aihara, M. (2011) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2010.01196.x · Cited by 108
Pirmohamed, M., Ostrov, D. A., & Park, B. K. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.022 · Cited by 108
Ng, C. Y., Yeh, Y.-T., Wang, C., Chung, W., Yang, C.-H., Chang, Y., Chang, W., Lin, Y., Chang, C., Su, S., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.02.808 · Cited by 108
“This association was later validated in many other populations (odds ratio [OR] 1⁄4 41e580) (Cao et al., 2012; Chiu et al., 2012; Goncalo et al., 2013; Jung et al., 2011; Kang et al., 2011; Kaniwa et al., 2008; Lee et al., 2012; Lonjou et al., 2008; Somkrua et al., 2011; Tassaneeyakul et al., 2009).”
BackgroundCao, Z., Wei, Z., Zhu, Q., Zhang, J., Yang, L., Qin, S., Shao, L., Zhang, Y., Xuan, J., Li, Q., et al. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.89 · Cited by 107
Ueta, M., Kaniwa, N., Sotozono, C., Tokunaga, K., Saito, Y., Sawai, H., Miyadera, H., Sugiyama, E., Maekawa, K., Nakamura, R., et al. (2014) · Scientific Reports · doi:10.1038/srep04862 · Cited by 107
Torres, M. J., Romano, A. G., Celik, G., Demoly, P. M., Khan, D. A., Macy, E. M., Park, M., Blumenthal, K. G., Aberer, W., Castells, M., et al. (2017) · Clinical and Translational Allergy · doi:10.1186/s13601-017-0144-0 · Cited by 106
“HLA-B*58:01 allele is associated with a high risk of allopurinol-induced DRESS and SJS/TEN in Asian and Caucasian populations [73, 74] and its screening is recommended by the American College of Rheumatology but not by the U.”
BackgroundPharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity
McEvoy, L., Carr, D. F., & Pirmohamed, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684162 · Cited by 105
Hsiao, Y., Hui, R. C., Wu, T., Chang, W., Hsih, M., Yang, C.-H., Ho, H., Chang, Y.-G., Chen, M., Lin, J.-Y., et al. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.10.003 · Cited by 102
“observed in Europeans, Japanese or Korean populations, who have lower frequencies of HLA-B*15:02 [11–14].”
BackgroundKim, S. C., Newcomb, C. W., Margolis, D. J., Roy, J., & Hennessy, S. (2012) · Arthritis Care & Research · doi:10.1002/acr.21817 · Cited by 102
Ocular surface inflammation is regulated by innate immunity
Ueta, M., & Kinoshita, S. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.05.003 · Cited by 102
Testing for drug hypersensitivity syndromes.
Rive, C. M., Bourke, J., & Phillips, E. J. (2013) · Europe PMC (PubMed Central) · Cited by 100
Avidity determines T ‐cell reactivity in abacavir hypersensitivity
Adam, J., Eriksson, K., Schnyder, B., Fontana, S., Pichler, W. J., & Yerly, D. (2012) · European Journal of Immunology · doi:10.1002/eji.201142159 · Cited by 99
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity
Lauschke, V. M., & Ingelman‐Sundberg, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101714 · Cited by 99
Metadata
- Authors
- Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., Schumacher, M., Roujeau, J.-C., Hovnanian, A., & Mockenhaupt, M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- University Medical Center Freiburg (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Ben-Gurion University of the Negev (IL)
- University of Milan (IT)
- Leiden University Medical Center (NL)
- Innsbruck Medical University (AT)
- Université Paris-Est Créteil (FR)
- Corresponding author
- Roujeau, Jean-Claude
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-02
- Volume
- 18
- Issue
- 2
- Pages
- 99-107
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025161685
- Cited by
- 624
- References
- 28
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 23 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 23 · 2019: 31 · 2018: 36 · 2017: 40 · 2016: 26 · 2015: 48 · 2014: 43 · 2013: 43 · 2012: 40
- FWCI
- 33.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- Stevens-Johnson syndrome, toxic epidermal necrolysis, HLA-B*58:01, HLA-B*15:02, allopurinol, sulfamethoxazole, lamotrigine, oxicams, drug-induced skin reaction, European populations, genetic susceptibility
- MeSH terms
- Adult, Aged, Base Sequence, Female, Humans, Male, Middle Aged, Stevens-Johnson Syndrome, HLA-B Antigens, DNA Primers, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.